{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:59:40Z","timestamp":1792115980141,"version":"4.4.0"},"reference-count":54,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Endocrinology"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>Glucagon-like peptide-1 receptor agonists have transformed obesity pharmacotherapy by producing substantial weight loss and, for semaglutide in patients with established cardiovascular disease, reducing major cardiovascular events. Integrating these therapies into primary care is constrained by gaps in provider training, clinical inertia, weight bias, high treatment costs, and fragmented insurance coverage. Racial and ethnic minority groups, low-income communities, and publicly insured patients are less likely to receive or fill prescriptions despite the disproportionate burden of obesity-related diseases. This narrative review examines primary care readiness, structural determinants of access, disparities in prescribing and use, real-world adherence, and policy options for these drugs. Without coordinated action, these therapies may reinforce a two-tiered treatment landscape in which access reflects socioeconomic advantages rather than clinical needs. Equitable implementation will require aligned reforms in coverage and pricing, workforce development, person-centered care, and long-term treatment support.<\/jats:p>","DOI":"10.1177\/20420188261472587","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T09:57:55Z","timestamp":1785146275000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["GLP-1 receptor agonists in primary care: readiness, equity, and the risk of a two-tiered obesity treatment landscape"],"prefix":"10.1177","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5991-4052","authenticated-orcid":false,"given":"Mohamed Mustaf","family":"Ahmed","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Health Sciences, SIMAD University, Mogadishu 252, Somalia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahmatullah","family":"Nazari","sequence":"additional","affiliation":[{"name":"Faculty of Dentistry, Cheragh Medical University, Kabul, Afghanistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3914-0867","authenticated-orcid":false,"given":"Zhinya Kawa","family":"Othman","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0138-3261","authenticated-orcid":false,"given":"Shuaibu Saidu","family":"Musa","sequence":"additional","affiliation":[{"name":"School of Global Health, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olalekan John","family":"Okesanya","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Science, Neuropsychiatric Hospital, Abeokuta, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2000-7451","authenticated-orcid":false,"given":"Uthman Okikiola","family":"Adebayo","sequence":"additional","affiliation":[{"name":"Department of Digital Health, Global Health Focus Africa, Kigali, Rwanda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Branda","sequence":"additional","affiliation":[{"name":"Unit of Medical Statistics and Molecular Epidemiology, Campus Bio-Medico University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5038-8017","authenticated-orcid":false,"given":"Abdullahi Hassan","family":"Elmi","sequence":"additional","affiliation":[{"name":"Department of Nursing, Faculty of Medicine and Health Sciences, Dr. Sumait Hospital, SIMAD University, Mogadishu, Somalia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Don Eliseo","family":"Lucero Prisno","sequence":"additional","affiliation":[{"name":"Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"e_1_3_4_2_2","unstructured":"World Health Organization (WHO). Obesity and overweight https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight (2025 accessed 12 April 2026)."},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02750-2"},{"key":"e_1_3_4_4_2","doi-asserted-by":"crossref","unstructured":"Bryan S et al. National Health and Nutrition Examination Survey 2017\u2014March 2020 Prepandemic data files-development of files and prevalence estimates for selected health outcomes. National Health Statistics Reports No. 158. Hyattsville MD: National Center for Health Statistics 2021.","DOI":"10.15620\/cdc:106273"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614362"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.20410"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/cob.70040"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/osp4.686"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40519-021-01217-1"},{"key":"e_1_3_4_13_2","unstructured":"Peterson-KFF Health System Tracker. How do prices of drugs for weight loss in the U.S. compare to peer nations\u2019 prices? https:\/\/www.healthsystemtracker.org\/brief\/prices-of-drugs-for-weight-loss-in-the-us-and-peer-nations\/ (2023 accessed 21 April 2026)."},{"key":"e_1_3_4_14_2","unstructured":"Wegovy. Want to save? You\u2019ve got options https:\/\/www.wegovy.com\/obesity\/what-to-pay-for-wegovy.html (2026 accessed 29 June 2026)."},{"key":"e_1_3_4_15_2","unstructured":"Investors. Zepbound (tirzepatide) the most prescribed weight management medication in 2025 Now available in multi-dose KwikPen. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/zepbound-tirzepatide-most-prescribed-weight-management (2026 accessed 29 June 2026)."},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15473"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.24288"},{"key":"e_1_3_4_18_2","unstructured":"World Health Organization (WHO). WHO issues global guideline on the use of GLP-1 medicines in treating obesity https:\/\/www.who.int\/news\/item\/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity (2025 accessed 21 April 2026)."},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-1678"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2019.09.010"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00337-8"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61721-8"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003114"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2003873"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03412-w"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511774"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02996-7"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/osp4.756"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0803-x"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2024.100120"},{"key":"e_1_3_4_31_2","article-title":"Weight stigma and bias: standards of care in overweight and obesity\u20142025","volume":"13","author":"Bannuru RR.","year":"2025","unstructured":"Bannuru RR. Weight stigma and bias: standards of care in overweight and obesity\u20142025. BMJ Open Diabetes Res Care 2025; 13(Suppl. 1): e004962.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-072686"},{"key":"e_1_3_4_33_2","unstructured":"ICER Analytics. ICER publishes final evidence report and policy recommendations on treatments for obesity management. Institute for Clinical and Economic Review (ICER) https:\/\/icer.org\/news-insights\/press-releases\/icer-publishes-final-evidence-report-and-policy-recommendations-on-treatments-for-obesity-management\/ (2022 accessed 21 April 2026)."},{"key":"e_1_3_4_34_2","unstructured":"ICER Analytics. Institute for clinical and economic review publishes final evidence report on treatments for obesity. Institute for Clinical and Economic Review (ICER) https:\/\/icer.org\/pressreleases\/institute-for-clinical-and-economic-review-publishes-final-evidence-report-on-treatments-for-obesity\/ (2025 accessed 21 April 2026)."},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2024.4657"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2025.0905"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-023-08416-9"},{"key":"e_1_3_4_38_2","article-title":"Semaglutide\u2019s CVD indication could cost US Medicare $145bn extra a year","volume":"386","author":"Mahase E.","year":"2024","unstructured":"Mahase E. Semaglutide\u2019s CVD indication could cost US Medicare $145bn extra a year. BMJ 2024; 386: q1878.","journal-title":"BMJ"},{"key":"e_1_3_4_39_2","unstructured":"Kaiser Family Foundation (KFF). Medicaid coverage of and spending on GLP-1s https:\/\/www.kff.org\/medicaid\/medicaid-coverage-of-and-spending-on-glp-1s\/ (2026 accessed 21 April 2026)."},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S392276"},{"key":"e_1_3_4_41_2","unstructured":"Peterson-KFF Health System Tracker. Perspectives from employers on the costs and issues associated with covering GLP-1 agonists for weight loss [Internet] https:\/\/www.healthsystemtracker.org\/brief\/perspectives-from-employers-on-the-costs-and-issues-associated-with-covering-glp-1-agonists-for-weight-loss\/ (2024 accessed 21 April 2026)."},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-022-01176-2"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2025.4258"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2412872121"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.069680"},{"issue":"9","key":"e_1_3_4_46_2","article-title":"Glucagon-like peptide-1 receptor agonists for arthritis and osteoarthritis","volume":"17","author":"Nashwan AJ.","year":"2025","unstructured":"Nashwan AJ. Glucagon-like peptide-1 receptor agonists for arthritis and osteoarthritis. Cureus 2025; 17(9): e93373.","journal-title":"Cureus"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.70638"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.glmedi.2024.100136"},{"issue":"11","key":"e_1_3_4_49_2","article-title":"Assessing the oncological safety of glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis","volume":"17","author":"Jaradat JH","year":"2025","unstructured":"Jaradat JH, et al. Assessing the oncological safety of glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis. Cureus 2025; 17(11): e96071.","journal-title":"Cureus"},{"issue":"8","key":"e_1_3_4_50_2","first-page":"860","article-title":"Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes","volume":"30","author":"Gleason PP","year":"2024","unstructured":"Gleason PP, Urick BY, Marshall LZ, et al. Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes. J Manag Care Spec Pharm 2024; 30(8): 860\u2013867.","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021-002517"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14725"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24336"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010145"},{"key":"e_1_3_4_55_2","unstructured":"CMA.gov. CMS launches voluntary model to expand access to life-changing medicines promote healthier living. Centers for Medicare & Medicaid Services (CMS) https:\/\/www.cms.gov\/newsroom\/press-releases\/cms-launches-voluntary-model-expand-access-life-changing-medicines-promote-healthier-living (2025 accessed 21 April 2026)."}],"container-title":["Therapeutic Advances in Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20420188261472587","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20420188261472587","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20420188261472587","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:16:53Z","timestamp":1785392213000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20420188261472587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":54,"alternative-id":["10.1177\/20420188261472587"],"URL":"https:\/\/doi.org\/10.1177\/20420188261472587","relation":{},"ISSN":["2042-0188","2042-0196"],"issn-type":[{"value":"2042-0188","type":"print"},{"value":"2042-0196","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"article-number":"20420188261472587"}}